Total Payments
$2,531
2024 Payments
$364.89
Companies
17
Transactions
129
Medicare Patients
7,596
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$2,470 (97.6%)
Education$60.55 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,470 | 125 | 97.6% |
| Education | $60.55 | 4 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Theravance Biopharma, Inc. | $415.18 | 25 | $0 (2018) |
| Shionogi Inc | $338.33 | 10 | $0 (2024) |
| Insmed, Inc. | $325.56 | 16 | $0 (2022) |
| Allergan, Inc. | $217.29 | 8 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $186.75 | 12 | $0 (2021) |
| Janssen Biotech, Inc. | $183.20 | 23 | $0 (2020) |
| AngioDynamics, Inc. | $133.28 | 3 | $0 (2023) |
| Janssen Products, LP | $125.00 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $123.45 | 7 | $0 (2024) |
| ABBVIE INC. | $112.90 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $364.89 | 13 | Shionogi Inc ($261.15) |
| 2023 | $377.42 | 14 | AngioDynamics, Inc. ($133.28) |
| 2022 | $165.73 | 7 | La Jolla Pharmaceutical Company ($49.95) |
| 2021 | $230.71 | 12 | Insmed, Inc. ($143.58) |
| 2020 | $137.80 | 9 | Insmed, Inc. ($36.47) |
| 2019 | $362.95 | 15 | Allergan Inc. ($141.35) |
| 2018 | $550.36 | 38 | Theravance Biopharma, Inc. ($212.66) |
| 2017 | $340.97 | 21 | Theravance Biopharma Inc. ($202.52) |
All Payment Transactions
129 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.14 | General |
| 10/09/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $27.94 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/19/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $101.25 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/16/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 08/06/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: ANTIFUNGALS | ||||||
| 07/31/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $29.48 | General |
| Category: Infections and Infectious Diseases | ||||||
| 07/29/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/27/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/05/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/15/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $27.10 | General |
| Category: Infections and Infectious Diseases | ||||||
| 04/30/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: ANTIFUNGALS | ||||||
| 02/14/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Infections and Infectious Diseases | ||||||
| 01/09/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $32.16 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/13/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $32.16 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/19/2023 | AngioDynamics, Inc. | ANGIOVAC (Device) | Food and Beverage | In-kind items and services | $76.23 | General |
| Category: VIT | ||||||
| 10/16/2023 | AngioDynamics, Inc. | ANGIOVAC (Device) | Food and Beverage | In-kind items and services | $12.31 | General |
| Category: VIT | ||||||
| 10/13/2023 | AngioDynamics, Inc. | ANGIOVAC (Device) | Food and Beverage | In-kind items and services | $44.74 | General |
| Category: VIT | ||||||
| 09/21/2023 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: HIV | ||||||
| 09/12/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/22/2023 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 08/18/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $32.75 | General |
| Category: Infections and Infectious Diseases | ||||||
| 07/27/2023 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 07/25/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/08/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.05 | General |
| 02/08/2023 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 2,039 | 200,470 | $1.3M | $377,100 |
| 2022 | 17 | 2,442 | 172,857 | $1.9M | $466,839 |
| 2021 | 16 | 1,759 | 149,677 | $1.4M | $342,381 |
| 2020 | 8 | 1,356 | 4,375 | $732,804 | $284,744 |
Total Patients
7,596
Total Services
527,379
Medicare Billing
$1.5M
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 512 | 2,107 | $337,120 | $135,433 | 40.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 507 | 558 | $239,940 | $76,725 | 32.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 163 | 1,101 | $154,140 | $56,326 | 36.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 184 | 307 | $69,075 | $29,636 | 42.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 189 | 273 | $68,250 | $27,850 | 40.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 114 | 145 | $33,064 | $10,085 | 30.5% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 58 | 191,941 | $191,941 | $8,638 | 4.5% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 65 | 604 | $54,360 | $6,267 | 11.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $12,220 | $6,190 | 50.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 31 | 233 | $27,960 | $5,351 | 19.1% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 39 | 278 | $27,800 | $4,546 | 16.4% |
| 36589 | Removal of tunneled central venous tube | Office | 2023 | 34 | 34 | $6,800 | $4,494 | 66.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $6,540 | $3,586 | 54.8% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 45 | 2,219 | $99,855 | $931.44 | 0.9% |
| J0692 | Injection, cefepime hydrochloride, 500 mg | Office | 2023 | 20 | 592 | $5,920 | $577.84 | 9.8% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 11 | 11 | $988.00 | $462.22 | 46.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 643 | 2,679 | $553,516 | $156,644 | 28.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 679 | 751 | $424,912 | $119,885 | 28.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 148 | 1,212 | $169,680 | $67,461 | 39.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 328 | 576 | $167,983 | $48,355 | 28.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 165 | 228 | $51,991 | $16,494 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 102 | 136 | $34,000 | $14,124 | 41.5% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2022 | 46 | 480 | $43,200 | $7,475 | 17.3% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2022 | 50 | 161,890 | $161,890 | $6,351 | 3.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $10,464 | $5,908 | 56.5% |
About Dr. Kurt Wiese, M.D
Dr. Kurt Wiese, M.D is a Infectious Disease healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942383096.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kurt Wiese, M.D has received a total of $2,531 in payments from pharmaceutical and medical device companies, with $364.89 received in 2024. These payments were reported across 129 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($2,470).
As a Medicare-enrolled provider, Wiese has provided services to 7,596 Medicare beneficiaries, totaling 527,379 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Boca Raton, FL
- Active Since 10/23/2006
- Last Updated 11/07/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1942383096
Products in Payments
- VIBATIV (Drug) $477.69
- Fetroja (Drug) $338.33
- Arikayce (Drug) $325.56
- AVYCAZ (Drug) $190.01
- PREZCOBIX (Drug) $181.56
- ANGIOVAC (Device) $133.28
- Symtuza (Drug) $112.45
- XERAVA (Drug) $108.85
- ISENTRESS (Drug) $108.27
- DALVANCE (Drug) $96.21
- NUZYRA (Drug) $63.43
- TEFLARO (Drug) $43.97
- Baxdela (Drug) $38.82
- DIFICID (Drug) $35.48
- Rezzayo (Drug) $34.48
- ZERBAXA (Drug) $28.02
- DOVATO (Drug) $22.22
- Yupelri (Drug) $21.13
- Cresemba (Drug) $18.45
- CUBICIN RF (Drug) $14.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Boca Raton
Dr. Steven Weber, M.d, M.D
Infectious Disease — Payments: $9,621
Infectious Disease $9,621
Ines Mbaga, Md, MD
Infectious Disease — Payments: $2,088
Infectious Disease $2,088
Susan Saxe, Md, MD
Infectious Disease — Payments: $1,798
Infectious Disease $1,798
Dr. Gabriel Sandkovsky, Md, MD
Infectious Disease — Payments: $1,534
Infectious Disease $1,534
Jane Elpedes Longares, M.d, M.D
Infectious Disease — Payments: $474.25
Infectious Disease $474.25
Julio Cardenas, Md, MD
Infectious Disease — Payments: $402.05
Infectious Disease $402.05